Consensus Zymeworks Inc.

Equities

ZYME

US98985Y1082

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.26 ^USD	+1.85%		-6.67%	-20.50%

Apr. 08	Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	CI
Apr. 04	Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	CI

Evolution of the average Target Price on Zymeworks Inc.

Price target over the last 5 years

History of analyst recommendation changes

5979b4e95461e.bEIqkuWRxBi1F8PoZj00H8fuDta45ZUM_FZIQyb2TXk.NDF1pL3Tlm3QfZPRCXdceqjZaKKJgtNcqhg9cE3BGRo7OnjEjeiKbPNO8w~df3a2057dd14bd059188fd837a48f9d8

Analyst Recommendations on Zymeworks Inc.

Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating	Mar. 12	MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	Mar. 11	MT
Citigroup Adjusts Price Target on Zymeworks to $18 From $17, Keeps Buy Rating	23-05-18	MT
Stifel Adjusts Price Target on Zymeworks to $19 From $18, Maintains Buy Rating	23-05-09	MT
JPMorgan Raises Zymeworks' Price Target to $9 From $8, Keeps Neutral Rating	23-03-31	MT
Wells Fargo Raises Price Target for Zymeworks to $12 From $9, Maintains Overweight Rating	23-02-13	MT
SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating	23-01-20	MT
HC Wainwright Adjusts Price Target on Zymeworks to $8 From $10, Maintains Neutral Rating	23-01-04	MT
Barclays Adjusts Zymeworks Price Target to $9 From $7, Maintains Equal Weight Rating	22-12-22	MT
Jefferies Upgrades Zymeworks to Buy From Hold, Adjusts Price Target to $11 From $7.70	22-12-20	MT
HC Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	22-11-21	MT
HC Wainwright Downgrades Zymeworks to Neutral From Buy, Lowers Price Target to $8 From $40	22-11-01	MT
Stifel Adjusts Zymeworks' Price Target to $18 From $21, Reiterates Buy Rating	22-10-24	MT
SVB Securities Downgrades Zymeworks to Market Perform From Outperform, Adjusts Price Target to $8 From $19	22-10-21	MT
Citigroup Lowers Zymeworks Price Target to $21 From $27, Maintains Buy Rating	22-09-13	MT
Citigroup Trims Price Target on Zymeworks to $27 From $28, Reiterates Buy Rating	22-08-29	MT
SVB Securities Adjusts Zymeworks' Price Target to $19 from $18, Keeps Outperform Rating	22-05-27	MT
HC Wainwright Adjusts Zymeworks' Price Target to $40 from $44, Keeps Buy Rating	22-05-23	MT
Citigroup Lowers Zymeworks Price Target to $28 From $30, Buy Rating Kept	22-05-09	MT
Guggenheim Upgrades Zymeworks to Buy From Neutral; Price Target is $14	22-05-05	MT
Evercore ISI Starts Zymeworks at Outperform With $15 Price Target	22-03-15	MT
Stifel Adjusts Price Target for Zymeworks to $24 From $51, Maintains Buy Rating	22-02-25	MT
Wells Fargo Adjusts Zymeworks' Price Target to $45 From $56, Reiterates Overweight Rating	22-02-09	MT
Raymond James Downgrades Zymeworks to Outperform From Strong Buy; Price Target is $74	21-12-10	MT
SVB Leerink Upgrades Zymeworks to Outperform From Market Perform	21-12-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.26 USD

Average target price

14.17 USD

Spread / Average Target

+71.51%

High Price Target

21 USD

Spread / Highest target

+154.24%

Low Price Target

10 USD

Spread / Lowest Target

+21.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Zymeworks Inc.

Wells Fargo Securities
HC Wainwright
Citigroup
Stifel Nicolaus
JPMorgan Chase
SVB Securities LLC
Barclays
Jefferies & Co.
Guggenheim
Evercore ISI
SVB Leerink
Raymond James
Credit Suisse

Ratings for Zymeworks Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar